| Literature DB >> 16757419 |
Sunil Gupta, Antonio Pagliuca, Steve Devereux, Ghulam J Mufti, Steve Schey.
Abstract
Bortezomib has been licensed to be used in relapsed and refractory multiple myeloma. It is a promising agent for this incurable condition but our effort is to caution hematologists about the life-threatening neurotoxicity (grade 4) which was seen in two of six patients treated with this agent although the complication cannot definitely be attributed to bortezomib.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16757419
Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941